Articles Tagged With: Influenza
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
Modified mRNA Influenza Vaccine Shows Superior Efficacy Over Standard Inactivated Vaccine
In a Phase III randomized controlled trial of adults aged 18 to 64 years, a quadrivalent nucleoside-modified messenger ribonucleic acid (mRNA) (modRNA) influenza vaccine demonstrated 34.5% relative efficacy against laboratory-confirmed influenza-like illness compared with a licensed inactivated influenza vaccine, meeting criteria for both noninferiority and superiority. The modRNA platform showed enhanced immunogenicity against influenza A strains and strong T-cell responses but did not meet noninferiority criteria for immunogenicity against influenza B strains (although clinical efficacy against B strains could not be determined due to low case counts). The modRNA vaccine was associated with increased reactogenicity but demonstrated an acceptable safety profile, supporting the potential of mRNA technology for next-generation influenza vaccines.
-
Comprehensive Data Analysis Validates the Effectiveness and Safety of COVID-19, RSV, and Influenza Vaccination
Respiratory syncytial virus, influenza, and COVID-19 vaccines are safe and effective.
-
Comprehensive Data Analysis Validates the Effectiveness and Safety of COVID-19, RSV, and Influenza Vaccination
Respiratory syncytial virus, influenza, and COVID-19 vaccines are safe and effective.
-
Current Recommendations for Childhood Respiratory Vaccines
Amidst prevalent vaccine hesitancy, changing governmental advisory groups, and altered recommendations, COVID immunization still is recommended for all children aged 6 through 23 months and for older children with medical risk factors.
-
The Seasonal Surge: Influenza in the ED
Influenza outbreaks occur each year, with their nature and extent largely determined by the virus’s glycoprotein structure and antigenic properties. These outbreaks typically occur during the winter months and can confer high morbidity to the general patient population. Increased mortality rates are seen in children younger than 5 years of age, older adults, and those with chronic comorbid medical conditions.
-
Influenza and Acute Necrotizing Encephalopathy in Children
Of 41 U.S. pediatric patients with influenza-associated acute necrotizing encephalitis, 56% were female, the median age was 5 years, and 12% had underlying complex medical conditions. Influenza A accounted for 95% of cases. Despite the use of a variety of immunomodulating agents, 27% of these children died, and 63% of the survivors were left with at least moderate disability.
-
Baloxavir Prevents Household Transmission of Influenza
Treatment with a single dose of baloxavir led to an adjusted relative risk reduction of 29% in household transmission of influenza compared to placebo. There was no significant difference in safety signals between baloxavir and placebo.
-
Oseltamivir for Adults Hospitalized with Influenza: Earlier Is Better
A multicenter observational study on adults hospitalized with influenza found that initiation of oseltamivir on the day of admission reduced the risk of disease progression, including pulmonary and extra-pulmonary organ failure and death.
-
Oseltamivir for Adults Hospitalized with Influenza: Earlier Is Better
A multicenter observational study on adults hospitalized with influenza found that initiation of oseltamivir on the day of admission reduced the risk of disease progression, including pulmonary and extra-pulmonary organ failure and death.